Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06288503
Other study ID # HRF2023
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 1, 2024
Est. completion date July 2027

Study information

Verified date February 2024
Source Nutricia UK Ltd
Contact Isabel Evans, MSc
Phone 07385000738
Email Isabel.EVANS@danone.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This non-inferiority study aims to determine whether a hydrolysed rice protein formula is as effective as a cow's milk protein based extensively hydrolysed formula using a double-blind, randomised-controlled design over a 28-day intervention period followed by a 2-month follow-up period in infants 0-13 months of age presenting with symptoms/clinical history suggestive of cow's milk allergy. The primary outcome is growth, and secondary outcomes are gastrointestinal tolerance, and differences in intake, allergic symptoms, parental QOL, acceptability, dietary intake, and safety.


Recruitment information / eligibility

Status Recruiting
Enrollment 86
Est. completion date July 2027
Est. primary completion date July 2027
Accepts healthy volunteers No
Gender All
Age group 0 Months to 13 Months
Eligibility Inclusion Criteria: - Male or female - Aged 0-13 months - Presenting to primary or secondary care with symptoms/clinical history suggestive of CMA - Will receive at least 30% of energy requirements from the study formula - Written informed consent from parent/carer Exclusion Criteria: - Severe CMA (including anaphylaxis) and/or requiring an AAF - Faltering growth (based on NICE guidelines36 - Appendix 1) - Previous allergy to any study product ingredients (including whey hydrolysate and/or rice) - Primary lactose intolerance - Food Protein-Induced Enterocolitis Syndrome (FPIES) - Exclusively breast fed - Severe concurrent or chronic disease or genetic syndrome that may impact growth or other outcomes - Severe hepatic or renal insufficiency - Premature infants (born <37 weeks) with a corrected age of <4 weeks - Requirement for any parenteral nutrition - Participation in other clinical intervention studies within 1 month of recruitment - Concern around the willingness/ability of the caregiver to comply with the study protocol and/or study requirements

Study Design


Intervention

Other:
Hydrolysed Rice Protein Formula
Infants randomised onto this arm will be taking the hydrolysed rice protein formula, with a minimum prescription of 30% of their energy requirements.
Cow's Milk Based Extensively Hydrolysed Formula
Infants randomised onto this arm will be taking the control product, with a minimum prescription of 30% of their energy requirements.

Locations

Country Name City State
United Kingdom Bristol Royal Hospital for Children Bristol Somerset
United Kingdom Gloucestershire Royal NHS Trust Gloucester Gloucestershire

Sponsors (1)

Lead Sponsor Collaborator
Nutricia UK Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Growth At Baseline (Day 1), End of Intervention (Day 31), and Follow-Up (Day 87) assessments, length and head circumference will be measured using standard measures to the nearest 0.1cm. Body weight (kg) will also be measured, where possible, by the investigating Dietitian/relevant HCP using standard methods to the nearest 0.1kg using a weighing scale without heavy clothing. These measures will be used to calculate z-scores (i.e., weight-for-length, weight, length, and head circumference; based on UK-WHO 2006 growth reference data for children 0-4 years old) and plotted on growth charts for centile measurement. Baseline to three months
Secondary Gastrointestinal Tolerance Gastrointestinal tolerance will be recorded by the parent/carer at Baseline Assessment and Baseline Days 1-3, where this period is undertaken by the patient), during the Intervention Period on Days 10, 17, 24, and 29-31, and during the 2-month Follow-Up period on Days 85-87. Tolerance will be recorded using a standardised GI tolerance questionnaire. Baseline to three months
Secondary Stool frequency and consistency Stool frequency and consistency (Brussels Infant and Toddler Stool Scale) will be recorded by the parent/carer at Baseline on Days 1-3 (where applicable), as well as on during the Intervention Period on Days 10, 17, 24, and 29-31, and during the 2-month Follow-Up on Days 85-87. Baseline to three months
Secondary Study Product Intake Intake of study product will be assessed daily throughout the Baseline and Intervention Periods by the parent/carer by recording how much feed was consumed. During the 2-month Follow-Up, intake of study product will be assessed for 3 days (Days 84-87). The daily minimum target intake amount prescribed by the investigating Dietitian/relevant HCP will be recorded at the start of the study, and any changes to this prescription will be noted. Baseline to three months
Secondary Patient Orientated Scoring Atopic Dermatitis Symptoms (PO-SCORAD) A self-evaluation tool will be completed by the parent/carer on the day of the Baseline Assessment (Day 1), on Days 10 and 31 during the Intervention Period, and on Day 87 during the 2-month Follow-Up to give an indication of severity of atopic dermatitis (where present). This will involve tick box questions and a diagram of an infant for the parent/carer to highlight presence of dermatitis. Baseline to three months
Secondary Patient Reported Atopic Symptoms The parent/carer will be asked to indicate their perception of the presence and severity of several common atopic symptoms for their child (wheezing, itchy/watery eyes, crying frequency, sneezing/runny/blocked nose, sleep quality) via 100mm visual analogue scales, with 100mm indicating more severe symptoms. These will be recorded on at Baseline Assessment (Day 1), on Day 3, Days 10, 17, 24, and 31 during the Intervention Period, and on Day 87 during the Follow-Up Period. Baseline to three months
Secondary Cow's Milk Related Symptom Score Infants' stool pattern, the presence and intensity of crying and regurgitation, as well as skin and respiratory manifestations will be assessed via the CoMiSS™ tool by the investigating Dietitian/relevant HCP at the Baseline (Day 1), End of Intervention (Day 31), and Follow-Up (Day 87) Assessments. Total scores range from 0-33, with higher number indicating more severe symptoms of cow's milk allergy. Baseline to three months
Secondary Food Allergy Quality of Life-Parental Burden (FAQL-PB) Parental measures of QOL (related to their child's allergy) will be assessed via a standardised validated questionnaire on the day of the Baseline Assessment (Day 1), on the final day of the Intervention Period (Day 31), and at the end of the Follow-Up Period (Day 87). Baseline to three months
Secondary Acceptability of the Study Formula Feed acceptability (e.g., ease of use, liking) will be assessed at Baseline (Day 3, where applicable), during the Intervention Period on Days 10 and 31, and at the end of the Follow-Up period on Day 87, via a Likert-style questionnaire completed by the parent/carer (strongly disagree/disagree/don't know/agree/strongly agree) Baseline to three months
Secondary Nutrient Intake (Energy, Protein, Micronutrients) Nutrient intake, including intake of all nutrition provided (including the study product, any other enteral feeding, foods, drinks etc.) will be recorded via a 24hr dietary recall conducted by the investigating Dietitian/relevant HCP at the Baseline (Day 1), Day 10, End of Intervention (Day 31), and Follow-Up (Day 87) Assessments. Dietary data will be inputted by the study team into nutritional software to estimate energy and macro- and micronutrient intakes. Baseline to three months
Secondary Dietetic Goal A dietetic goal (e.g., improve tolerance, reduce atopic symptoms, maintain symptom control, maintain normal growth) will be set by the investigating Dietitian/relevant HCP at the Baseline Assessment (Day 1) for each infant. At the End of Intervention Assessment (Day 31), the investigating Dietitian/relevant HCP will assess and note if the dietetic goal was met (yes/no) and will set a dietetic goal for the Follow-Up Period. At the Follow-Up Assessment (Day 87), the investigating Dietitian/relevant HCP will assess and note if the dietetic goal was met (yes/no). Baseline to three months
Secondary Overall Safety All adverse events will be recorded throughout the study. Through study completion, an average of three months
See also
  Status Clinical Trial Phase
Completed NCT04596059 - The Journey of Children With Cow's Milk Protein Allergy in Mexico.
Not yet recruiting NCT06130085 - Partially Hydrolyzed Formula in Cow's Milk Protein Allergy After 6 Months of Elimination N/A
Completed NCT03769051 - Study on The Oral Immune Tolerance of CMPA Infants Using Amino Acid Formula
Completed NCT02953223 - A Study to Monitor the Use of an Amino Acid-Based Infant Formula
Completed NCT03085134 - Clinical Safety & Efficacy of a New Infant Formula With Specific Medical Purpose Containing Human Milk Oligosaccharides N/A
Completed NCT06273371 - Tolerance and Growth Outcomes in Children Diagnosed With Cow's Milk Protein Allergy and Prescribed an Extensively Hydrolyzed Casein Formula (Damira 2000©) in Spain